Emerald Investment Advisers LLC bought a new position in shares of AtriCure, Inc. (NASDAQ:ATRC – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 79,102 shares of the medical device company’s stock, valued at approximately $2,213,000.
A number of other institutional investors and hedge funds have also bought and sold shares of ATRC. Geneos Wealth Management Inc. acquired a new position in shares of AtriCure in the second quarter valued at approximately $37,000. Harbor Investment Advisory LLC acquired a new position in AtriCure in the 2nd quarter valued at $40,000. Allworth Financial LP acquired a new stake in shares of AtriCure during the 2nd quarter worth $43,000. Smartleaf Asset Management LLC increased its position in shares of AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after purchasing an additional 429 shares during the period. Finally, Fifth Third Bancorp acquired a new position in AtriCure in the first quarter valued at about $51,000. Institutional investors and hedge funds own 99.11% of the company’s stock.
Wall Street Analysts Forecast Growth
ATRC has been the subject of several recent analyst reports. Weiss Ratings raised shares of AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday. Zacks Research raised shares of AtriCure from a “hold” rating to a “strong-buy” rating in a report on Friday, July 24th. Raymond James Financial set a $52.00 target price on shares of AtriCure in a research report on Tuesday, July 21st. Wall Street Zen downgraded shares of AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, Canaccord Genuity Group increased their price target on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.50.
Insider Transactions at AtriCure
In related news, insider Justin J. Noznesky sold 6,182 shares of AtriCure stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $38.80, for a total transaction of $239,861.60. Following the sale, the insider directly owned 100,219 shares of the company’s stock, valued at approximately $3,888,497.20. The trade was a 5.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Karen Prange sold 3,564 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total transaction of $138,283.20. Following the transaction, the director owned 22,809 shares of the company’s stock, valued at approximately $884,989.20. This represents a 13.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 44,246 shares of company stock valued at $1,691,895. 4.00% of the stock is owned by company insiders.
AtriCure Price Performance
AtriCure stock opened at $48.98 on Friday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. AtriCure, Inc. has a 52 week low of $25.36 and a 52 week high of $49.20. The stock has a market capitalization of $2.49 billion, a P/E ratio of 233.25 and a beta of 1.20. The stock has a fifty day moving average of $35.83 and a 200-day moving average of $31.84.
AtriCure (NASDAQ:ATRC – Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The business had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. During the same period last year, the firm posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, sell-side analysts expect that AtriCure, Inc. will post 0.2 earnings per share for the current fiscal year.
AtriCure Profile
AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.
The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.
Featured Stories
- Five stocks we like better than AtriCure
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC – Free Report).
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
